Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology PipelineBusiness Wire • 01/05/24
Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)Seeking Alpha • 01/04/24
Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with InspirnaBusiness Wire • 01/04/24
Merck: An Excellent Dividend Grower With Strong Annual Total Return PotentialSeeking Alpha • 12/25/23
Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And GrowthSeeking Alpha • 12/25/23
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung CancerBusiness Wire • 12/22/23
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted ConferenceBusiness Wire • 12/20/23